News articles about Horizon Pharma PLC (NASDAQ:HZNP) have trended somewhat positive recently, AlphaOne Sentiment reports. AlphaOne, a service of Accern, identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Pharma PLC earned a coverage optimism score of 0.19 on AlphaOne’s scale. AlphaOne also gave news headlines about the biopharmaceutical company an impact score of 97 out of 100, meaning that recent news coverage is extremely likely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Alpha One’s scoring:
- Horizon Pharma (HZNP) Announces Health Canada Approval of PROCYSBI for Treatment of Nephropathic Cystinosis (streetinsider.com)
- Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine … (globenewswire.com)
- Horizon Pharma plc (NASDAQ:HZNP) Trading Up – Short Interest Up by 5.27% (highlightpress.com)
- Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis (finance.yahoo.com)
- Horizon Pharma Ord (HZNP) A Look at Technical Overview (nyhetsbanken.info)
Shares of Horizon Pharma PLC (HZNP) traded up 3.879% during midday trading on Tuesday, hitting $11.115. 2,852,891 shares of the stock traded hands. The company’s market cap is $1.81 billion. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $23.44. The stock has a 50-day moving average of $11.23 and a 200-day moving average of $14.81.
Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by $0.04. Horizon Pharma PLC had a negative net margin of 21.26% and a positive return on equity of 21.51%. The company had revenue of $220.90 million for the quarter, compared to analyst estimates of $248.71 million. During the same quarter in the prior year, the business earned $0.34 earnings per share. Horizon Pharma PLC’s revenue was up 7.9% on a year-over-year basis. On average, equities analysts predict that Horizon Pharma PLC will post $0.84 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on HZNP. Cantor Fitzgerald began coverage on shares of Horizon Pharma PLC in a report on Friday. They issued an “overweight” rating and a $13.00 target price on the stock. ValuEngine downgraded shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. reduced their target price on shares of Horizon Pharma PLC from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. Jefferies Group LLC set a $14.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Tuesday, May 9th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price (down from $35.00) on shares of Horizon Pharma PLC in a report on Tuesday, May 9th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $20.77.
COPYRIGHT VIOLATION NOTICE: “Horizon Pharma PLC (HZNP) Getting Somewhat Favorable News Coverage, AlphaOne Reports” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2655683/horizon-pharma-plc-hznp-getting-somewhat-favorable-news-coverage-alphaone-reports.html.
In other Horizon Pharma PLC news, Director Michael G. Grey acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was purchased at an average price of $9.48 per share, for a total transaction of $94,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.20% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.